A regulatory perspective on the evaluation of hallucinogen drugs for human use
In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the...
Saved in:
| Published in | Neuropharmacology Vol. 142; pp. 135 - 142 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.11.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA.
This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’.
•The USA regulatory framework that applies to the development of hallucinogenic drugs is the same as for all other drugs.•The safety and effectiveness of a drug for its intended use must be demonstrated to approve the drug for marketing.•The abuse potential of a drug is one safety factor that needs to be evaluated.•Characterization of the abuse potential of a drug informs labeling, risk management strategies, and controls.•Some hallucinogens show promise in medical treatment; however, their overall safety and efficacy still need to be evaluated. |
|---|---|
| AbstractList | In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'. In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'. In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be subject to controls to minimize the abuse of the drug once on the market. This assessment is conducted for all new drugs with central nervous system (CNS) activity, that are chemically or pharmacologically similar to other drugs with known abuse potential, or drugs that produce psychoactive effects predictive of abuse, such as euphoria and hallucinations. This paper describes the regulatory framework for evaluating the abuse potential of new drugs, with emphasis on hallucinogens. The paper discusses the role of the United States Food and Drug Administration (FDA) in the evaluation of the abuse potential of drugs and its role in drug control, and provides an overview of the controlled status of hallucinogens and the requirements to conduct research with Schedule I substances in the USA. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’. •The USA regulatory framework that applies to the development of hallucinogenic drugs is the same as for all other drugs.•The safety and effectiveness of a drug for its intended use must be demonstrated to approve the drug for marketing.•The abuse potential of a drug is one safety factor that needs to be evaluated.•Characterization of the abuse potential of a drug informs labeling, risk management strategies, and controls.•Some hallucinogens show promise in medical treatment; however, their overall safety and efficacy still need to be evaluated. |
| Author | Hunt, Joshua Klein, Michael Calderon, Silvia N. |
| Author_xml | – sequence: 1 givenname: Silvia N. surname: Calderon fullname: Calderon, Silvia N. email: silvia.calderon@fda.hhs.gov organization: Controlled Substance Staff, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA – sequence: 2 givenname: Joshua surname: Hunt fullname: Hunt, Joshua organization: Controlled Substance Staff, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA – sequence: 3 givenname: Michael surname: Klein fullname: Klein, Michael organization: IQVIA™, 8630 Fenton Street, Silver Spring, MD, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29180224$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU9r3DAQxUVJaTZJv0LRsRe7I1lryZdCGvoPQnNpzkKWx7tabMmVrIV8-yrZhEIv7WmY4b03zG8uyJkPHgmhDGoGrP1wqD3mGJa9iXPNgcmasRq4ekU2TMmmktCKM7KBMqqaDtQ5uUjpAABCMfWGnPOOKeBcbMiPaxpxlyezhvhAF4xpQbu6I9Lg6bpHikczZbO60oaR7s00Zet82KGnQ8y7RMcQ6T7PxtOc8Iq8Hs2U8O1zvST3Xz7_vPlW3d59_X5zfVtZAbBW25Z3Ix9QigHUFnrbc-BSdu243faDNaxnEgEbHBrTSMuFbU0vlRA9s1BszSV5f8pdYviVMa16dsniNBmPISfNurbrGtE2qkjfPUtzP-Ogl-hmEx_0C4Mi-HgS2BhSijhq69ani9do3KQZ6Efo-qD_QNeP0DVjuhAuAeqvgJcd_2H9dLJigXV0GHWyDr3FwcXyBz0E9--Q34bpo7I |
| CitedBy_id | crossref_primary_10_1007_s11033_020_06009_x crossref_primary_10_1007_s11469_023_01163_2 crossref_primary_10_1177_02698811221140004 crossref_primary_10_1177_07067437221111371 crossref_primary_10_1016_j_neuropharm_2022_109220 crossref_primary_10_1016_j_neuropharm_2022_109352 crossref_primary_10_1016_j_jpain_2022_05_003 crossref_primary_10_1016_j_neuropharm_2018_08_024 crossref_primary_10_1016_j_neuropharm_2022_109375 crossref_primary_10_1016_j_microc_2024_112251 crossref_primary_10_1080_14740338_2022_2063274 crossref_primary_10_1080_02791072_2021_1941444 |
| Cites_doi | 10.1007/s40262-017-0540-6 10.1016/j.vascn.2016.07.004 10.1177/0269881108093587 10.1001/archpsyc.63.8.856 10.1097/00000542-199801000-00015 10.4088/JCP.13m08852 10.1016/j.biopsych.2012.06.022 10.1002/hup.1196 10.1146/annurev.pa.09.040169.002411 10.1007/s00213-003-1485-z 10.1037/1064-1297.14.4.439 10.1016/S0376-8716(03)00099-1 10.1080/02791072.1991.10472572 10.1001/jama.2017.9205 10.1016/S0376-8716(03)00098-X 10.1007/BF00432363 10.1177/0004867416631828 10.1021/acs.jmedchem.7b00085 10.1001/archgenpsychiatry.2010.116 10.1038/sj.clpt.6100492 10.1016/S0022-3565(25)31050-5 10.1097/00008877-200403000-00007 10.1176/appi.ajp.2013.13030392 10.4088/JCP.15m10056 10.1016/j.neuropharm.2014.04.001 10.1016/S0006-3223(99)00230-9 10.1007/s00213-012-2912-9 10.1097/00008877-199811000-00002 10.1038/80577 10.1038/clpt.2011.20 10.1093/ijnp/pyv065 10.1016/0166-4328(96)00081-2 10.1016/S0376-8716(03)00097-8 10.4088/JCP.10l06447blu 10.1016/j.biopsych.2009.08.038 10.1001/archpsyc.1994.03950020009001 10.1001/archpsyc.1994.03950020022002 10.1016/j.biopsych.2009.04.029 10.1016/0091-3057(87)90587-9 10.1007/s00213-003-1484-0 10.1037/pha0000084 |
| ContentType | Journal Article |
| Copyright | 2017 Published by Elsevier Ltd. |
| Copyright_xml | – notice: 2017 – notice: Published by Elsevier Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.neuropharm.2017.11.028 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-7064 |
| EndPage | 142 |
| ExternalDocumentID | 29180224 10_1016_j_neuropharm_2017_11_028 S0028390817305373 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29N 3O- 4.4 41~ 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXLA AAXUO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADIYS ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMQ HMT HVGLF HZ~ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SNS SPCBC SPT SSN SSP SSZ T5K TEORI WUQ X7M XOL ZGI ZXP ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c400t-5629f2de74d0850bcb2027796f55bdca1b17e0e3ed3a37c24c6ab7844b1c0de73 |
| IEDL.DBID | .~1 |
| ISSN | 0028-3908 1873-7064 |
| IngestDate | Fri Jul 11 00:59:55 EDT 2025 Mon Jul 21 05:48:03 EDT 2025 Thu Jul 03 08:46:36 EDT 2025 Thu Apr 24 22:51:13 EDT 2025 Fri Feb 23 02:34:51 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Abuse potential hallucinogens Hallucinogens regulations Controlled hallucinogens |
| Language | English |
| License | Published by Elsevier Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c400t-5629f2de74d0850bcb2027796f55bdca1b17e0e3ed3a37c24c6ab7844b1c0de73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 29180224 |
| PQID | 1969934638 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1969934638 pubmed_primary_29180224 crossref_citationtrail_10_1016_j_neuropharm_2017_11_028 crossref_primary_10_1016_j_neuropharm_2017_11_028 elsevier_sciencedirect_doi_10_1016_j_neuropharm_2017_11_028 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-11-01 |
| PublicationDateYYYYMMDD | 2018-11-01 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Neuropharmacology |
| PublicationTitleAlternate | Neuropharmacology |
| PublicationYear | 2018 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Johnson, Richards, Griffiths (bib27) 2008; 22 Murrough, Iosifescu, Chang, Al Jurdi, Green, Perez, Iqbal, Pillemer, Foulkes, Shah, Charney, Mathew (bib34) 2013; 170 Strassman (bib44) 1994; 146 Ionescu, Swee, Pavone, Taylor, Akeju, Baer, Nyer, Cassano, Mischoulon, Alpert, Brown, Nock, Fava, Cusin (bib25) 2016; 77 aan het Rot, Collins, Murrough, Perez, Reich, Charney, Mathew (bib1) 2010; 67 Wan, Levitch, Perez, Brallier, Iosifescu, Chang, Foulkes, Mathew, Charney, Murrough (bib50) 2015; 76 WHO (bib51) 1961 Bowdle, Radant, Cowley, Kharasch, Strassman, Roy-Byrne (bib6) 1998; 88 ICH (bib24) 2009 Maqueda, Valle, Addy, Antonijoan, Puntes, Coimbra, Ballester, Garrido, Gonzalez, Claramunt, Barker, Johnson, Griffiths, Riba (bib31) 2015; 18 Goodwin (bib18) 2016; 82 FDA/CDER (bib14) 2017 Grob, Danforth, Chopra, Hagerty, McKay, Halberstadt, Greer (bib22) 2011; 68 NACDA (bib37) 2006 Lofwall, Griffiths, Mintzer (bib29) 2006; 14 EMCDDA (bib11) 2017 Strassman, Qualls (bib46) 1994; 51 DEA (bib10) 2017 Calderon, Klein (bib8) 2014; 87 Murrough, Perez, Mathew, Charney (bib35) 2011; 72 Murrough, Perez, Pillemer, Stern, Parides, aan het Rot, Collins, Mathew, Charney, Iosifescu (bib36) 2013; 74 WHO (bib52) 1971 Fantegrossi, Woods, Winger (bib13) 2004; 15 Griffiths (bib20) 2014 Gottlieb, Woodcock (bib19) 2017; 318 Brown, Nicholas, Cozzi, Gassman, Cooper, Muller, Thomas, Hetzel, Henriquez, Ribaudo, Hutson (bib7) 2017; 56 EMEA/CHMP (bib12) 2006 Fischman, Johanson (bib15) 1998; 9 Cusin, Ionescu, Pavone, Akeju, Cassano, Taylor, Eikermann, Durham, Swee, Chang, Dording, Soskin, Kelley, Mischoulon, Brown, Fava (bib9) 2017; 51 Ator, Griffiths (bib2) 2003; 70 MacLean, Johnson, Reissig, Prisinzano, Griffiths (bib30) 2013; 226 Strassman, Qualls, Uhlenhuth, Kellner (bib47) 1994; 51 Berman, Cappiello, Anand, Oren, Heninger, Charney, Krystal (bib5) 2000; 47 Johanson, Balster (bib26) 1978; 30 Balster, Bigelow (bib3) 2003; 70 Schuster, Thompson (bib41) 1969; 9 Strassman (bib43) 1991; 23 Health Canada (bib23) 2007 Balster, Woolverton (bib4) 1980; 70 Schoedel, Sellers (bib40) 2008; 83 Tanda, Munzar, Goldberg (bib49) 2000; 3 Tanda, Goldberg (bib48) 2003; 169 Glennon (bib17) 2017; 60 Shram, Schoedel, Bartlett, Shazer, Anderson, Sellers (bib42) 2011; 89 Zarate, Singh, Carlson, Brutsche, Ameli, Luckenbaugh, Charney, Manji (bib53) 2006; 63 Marquis, Moreton (bib32) 1987; 27 Moreton, Meisch, Stark, Thompson (bib33) 1977; 203 Schoedel, Chen, Hilliard, White, Stott, Russo, Wright, Guy, Romach, Sellers (bib39) 2011; 26 Price, Nock, Charney, Mathew (bib38) 2009; 66 Strassman (bib45) 1996; 73 Garcia-Romeu, Kersgaard, Addy (bib16) 2016; 24 Griffiths, Bigelow, Ator (bib21) 2003; 70 Justinova, Tanda, Redhi, Goldberg (bib28) 2003; 169 Ator (10.1016/j.neuropharm.2017.11.028_bib2) 2003; 70 Justinova (10.1016/j.neuropharm.2017.11.028_bib28) 2003; 169 Moreton (10.1016/j.neuropharm.2017.11.028_bib33) 1977; 203 Glennon (10.1016/j.neuropharm.2017.11.028_bib17) 2017; 60 Lofwall (10.1016/j.neuropharm.2017.11.028_bib29) 2006; 14 ICH (10.1016/j.neuropharm.2017.11.028_bib24) 2009 Johanson (10.1016/j.neuropharm.2017.11.028_bib26) 1978; 30 Goodwin (10.1016/j.neuropharm.2017.11.028_bib18) 2016; 82 Schoedel (10.1016/j.neuropharm.2017.11.028_bib40) 2008; 83 Cusin (10.1016/j.neuropharm.2017.11.028_bib9) 2017; 51 EMEA/CHMP (10.1016/j.neuropharm.2017.11.028_bib12) 2006 Murrough (10.1016/j.neuropharm.2017.11.028_bib35) 2011; 72 WHO (10.1016/j.neuropharm.2017.11.028_bib51) 1961 Tanda (10.1016/j.neuropharm.2017.11.028_bib48) 2003; 169 Grob (10.1016/j.neuropharm.2017.11.028_bib22) 2011; 68 Wan (10.1016/j.neuropharm.2017.11.028_bib50) 2015; 76 WHO (10.1016/j.neuropharm.2017.11.028_bib52) 1971 Price (10.1016/j.neuropharm.2017.11.028_bib38) 2009; 66 Gottlieb (10.1016/j.neuropharm.2017.11.028_bib19) 2017; 318 Johnson (10.1016/j.neuropharm.2017.11.028_bib27) 2008; 22 Tanda (10.1016/j.neuropharm.2017.11.028_bib49) 2000; 3 Marquis (10.1016/j.neuropharm.2017.11.028_bib32) 1987; 27 Murrough (10.1016/j.neuropharm.2017.11.028_bib34) 2013; 170 Strassman (10.1016/j.neuropharm.2017.11.028_bib46) 1994; 51 Calderon (10.1016/j.neuropharm.2017.11.028_bib8) 2014; 87 Griffiths (10.1016/j.neuropharm.2017.11.028_bib21) 2003; 70 EMCDDA (10.1016/j.neuropharm.2017.11.028_bib11) 2017 Schoedel (10.1016/j.neuropharm.2017.11.028_bib39) 2011; 26 Strassman (10.1016/j.neuropharm.2017.11.028_bib43) 1991; 23 Balster (10.1016/j.neuropharm.2017.11.028_bib4) 1980; 70 NACDA (10.1016/j.neuropharm.2017.11.028_bib37) 2006 Schuster (10.1016/j.neuropharm.2017.11.028_bib41) 1969; 9 Fantegrossi (10.1016/j.neuropharm.2017.11.028_bib13) 2004; 15 aan het Rot (10.1016/j.neuropharm.2017.11.028_bib1) 2010; 67 Brown (10.1016/j.neuropharm.2017.11.028_bib7) 2017; 56 Ionescu (10.1016/j.neuropharm.2017.11.028_bib25) 2016; 77 MacLean (10.1016/j.neuropharm.2017.11.028_bib30) 2013; 226 Shram (10.1016/j.neuropharm.2017.11.028_bib42) 2011; 89 Health Canada (10.1016/j.neuropharm.2017.11.028_bib23) 2007 Strassman (10.1016/j.neuropharm.2017.11.028_bib47) 1994; 51 Griffiths (10.1016/j.neuropharm.2017.11.028_bib20) 2014 Murrough (10.1016/j.neuropharm.2017.11.028_bib36) 2013; 74 Berman (10.1016/j.neuropharm.2017.11.028_bib5) 2000; 47 Fischman (10.1016/j.neuropharm.2017.11.028_bib15) 1998; 9 Balster (10.1016/j.neuropharm.2017.11.028_bib3) 2003; 70 DEA (10.1016/j.neuropharm.2017.11.028_bib10) 2017 FDA/CDER (10.1016/j.neuropharm.2017.11.028_bib14) 2017 Zarate (10.1016/j.neuropharm.2017.11.028_bib53) 2006; 63 Garcia-Romeu (10.1016/j.neuropharm.2017.11.028_bib16) 2016; 24 Strassman (10.1016/j.neuropharm.2017.11.028_bib45) 1996; 73 Maqueda (10.1016/j.neuropharm.2017.11.028_bib31) 2015; 18 Bowdle (10.1016/j.neuropharm.2017.11.028_bib6) 1998; 88 Strassman (10.1016/j.neuropharm.2017.11.028_bib44) 1994; 146 |
| References_xml | – volume: 203 start-page: 303 year: 1977 end-page: 309 ident: bib33 article-title: Ketamine self-administration by the rhesus monkey publication-title: J. Pharmacol. Exp. Ther. – volume: 51 start-page: 98 year: 1994 end-page: 108 ident: bib47 article-title: Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale publication-title: Arch. Gen. Psychiatry – volume: 47 start-page: 351 year: 2000 end-page: 354 ident: bib5 article-title: Antidepressant effects of ketamine in depressed patients publication-title: Biol. Psychiatry – volume: 82 start-page: 31 year: 2016 end-page: 36 ident: bib18 article-title: An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates publication-title: J. Pharmacol. Toxicol. Methods – volume: 318 start-page: 421 year: 2017 end-page: 422 ident: bib19 article-title: Marshaling FDA benefit-risk expertise to address the current opioid abuse epidemic publication-title: JAMA – year: 2017 ident: bib14 article-title: Guidance for Industry- Assessment of Abuse Potential of Drugs – volume: 67 start-page: 139 year: 2010 end-page: 145 ident: bib1 article-title: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression publication-title: Biol. Psychiatry – volume: 30 start-page: 43 year: 1978 end-page: 54 ident: bib26 article-title: A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys publication-title: Bull. Narc. – volume: 170 start-page: 1134 year: 2013 end-page: 1142 ident: bib34 article-title: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial publication-title: Am. J. Psychiatry – volume: 70 start-page: 5 year: 1980 end-page: 10 ident: bib4 article-title: Continuous-access phencyclidine self-administration by rhesus monkeys leading to physical dependence publication-title: Psychopharmacol. Berl. – volume: 72 start-page: 414 year: 2011 end-page: 415 ident: bib35 article-title: A case of sustained remission following an acute course of ketamine in treatment-resistant depression publication-title: J. Clin. Psychiatry – volume: 89 start-page: 683 year: 2011 end-page: 692 ident: bib42 article-title: Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users publication-title: Clin. Pharmacol. Ther. – year: 1971 ident: bib52 article-title: World Health Organization, United Nations Convention on Psychotropic Substances – volume: 63 start-page: 856 year: 2006 end-page: 864 ident: bib53 article-title: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression publication-title: Arch. Gen. Psychiatry – volume: 68 start-page: 71 year: 2011 end-page: 78 ident: bib22 article-title: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer publication-title: Arch. Gen. Psychiatry – volume: 83 start-page: 622 year: 2008 end-page: 626 ident: bib40 article-title: Assessing abuse liability during drug development: changing standards and expectations publication-title: Clin. Pharmacol. Ther. – volume: 169 start-page: 135 year: 2003 end-page: 140 ident: bib28 article-title: Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys publication-title: Psychopharmacol. Berl. – volume: 3 start-page: 1073 year: 2000 end-page: 1074 ident: bib49 article-title: Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys publication-title: Nat. Neurosci. – year: 2014 ident: bib20 article-title: Pilot Study: Effects of Psylocibin on Behavior, Psychology and Brain Function in Long-term Meditators – volume: 70 start-page: S13 year: 2003 end-page: S40 ident: bib3 article-title: Guidelines and methodological reviews concerning drug abuse liability assessment publication-title: Drug Alcohol Depend. – volume: 146 start-page: 92 year: 1994 end-page: 123 ident: bib44 article-title: Human hallucinogenic drug research: regulatory, clinical, and scientific issues publication-title: NIDA Res. Monogr. – volume: 9 start-page: 479 year: 1998 end-page: 498 ident: bib15 article-title: Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers publication-title: Behav. Pharmacol. – volume: 88 start-page: 82 year: 1998 end-page: 88 ident: bib6 article-title: Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations publication-title: Anesthesiology – volume: 51 start-page: 85 year: 1994 end-page: 97 ident: bib46 article-title: Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects publication-title: Arch. Gen. Psychiatry – volume: 15 start-page: 149 year: 2004 end-page: 157 ident: bib13 article-title: Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys publication-title: Behav. Pharmacol. – year: 2006 ident: bib37 article-title: National Advisory Council on Drug Abuse – volume: 87 start-page: 97 year: 2014 end-page: 103 ident: bib8 article-title: A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States publication-title: Neuropharmacology – volume: 56 start-page: 1543 year: 2017 end-page: 1554 ident: bib7 article-title: Pharmacokinetics of escalating doses of oral psilocybin in healthy adults publication-title: Clin. Pharmacokinet. – year: 2017 ident: bib11 article-title: European Monitoring Centre for Drugs and Drug Addiction Website. Legal Topic Overviews: Classification of Controlled Subtances – volume: 73 start-page: 121 year: 1996 end-page: 124 ident: bib45 article-title: Human psychopharmacology of N,N-dimethyltryptamine publication-title: Behav. Brain Res. – volume: 70 start-page: S55 year: 2003 end-page: S72 ident: bib2 article-title: Principles of drug abuse liability assessment in laboratory animals publication-title: Drug Alcohol Depend. – year: 2017 ident: bib10 article-title: Lists of Scheduling Actions, Controlled Substances, Regulated Chemicals – volume: 24 start-page: 229 year: 2016 end-page: 268 ident: bib16 article-title: Clinical applications of hallucinogens: a review publication-title: Exp. Clin. Psychopharmacol. – volume: 14 start-page: 439 year: 2006 end-page: 449 ident: bib29 article-title: Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults publication-title: Exp. Clin. Psychopharmacol. – volume: 226 start-page: 381 year: 2013 end-page: 392 ident: bib30 article-title: Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects publication-title: Psychopharmacol. Berl. – volume: 22 start-page: 603 year: 2008 end-page: 620 ident: bib27 article-title: Human hallucinogen research: guidelines for safety publication-title: J. Psychopharmacol. – volume: 74 start-page: 250 year: 2013 end-page: 256 ident: bib36 article-title: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression publication-title: Biol. Psychiatry – year: 1961 ident: bib51 article-title: World Health Organization, United Nations Single Convention on Narcotic Drugs – volume: 26 start-page: 224 year: 2011 end-page: 236 ident: bib39 article-title: A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use publication-title: Hum. Psychopharmacol. – year: 2006 ident: bib12 article-title: Guidance for He Non-clinical Investigation of the Dependence Potential of Medicinal Products – volume: 76 start-page: 247 year: 2015 end-page: 252 ident: bib50 article-title: Ketamine safety and tolerability in clinical trials for treatment-resistant depression publication-title: J. Clin. Psychiatry – volume: 60 start-page: 2605 year: 2017 end-page: 2628 ident: bib17 article-title: The 2014 Philip S. Portoghese medicinal chemistry lectureship: the “Phenylalkylaminome” with a focus on selected drugs of abuse dagger publication-title: J. Med. Chem. – volume: 77 start-page: e719 year: 2016 end-page: 725 ident: bib25 article-title: Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study publication-title: J. Clin. Psychiatry – year: 2009 ident: bib24 article-title: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2) – volume: 66 start-page: 522 year: 2009 end-page: 526 ident: bib38 article-title: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression publication-title: Biol. Psychiatry – volume: 18 year: 2015 ident: bib31 article-title: Salvinorin-a induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans publication-title: Int. J. Neuropsychopharmacol. – volume: 51 start-page: 55 year: 2017 end-page: 64 ident: bib9 article-title: Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation publication-title: Aust. N. Z. J. Psychiatry – volume: 23 start-page: 29 year: 1991 end-page: 38 ident: bib43 article-title: Human hallucinogenic drug research in the United States: a present-day case history and review of the process publication-title: J. Psychoact. Drugs – volume: 70 start-page: S41 year: 2003 end-page: S54 ident: bib21 article-title: Principles of initial experimental drug abuse liability assessment in humans publication-title: Drug Alcohol Depend. – year: 2007 ident: bib23 article-title: Minister of Health. Guidance Document on the Clinical Assessment of Abuse Liability for Drugs with Central Nervous System Activity – volume: 27 start-page: 385 year: 1987 end-page: 389 ident: bib32 article-title: Animal models of intravenous phencyclinoid self-administration publication-title: Pharmacol. Biochem. Behav. – volume: 169 start-page: 115 year: 2003 end-page: 134 ident: bib48 article-title: Cannabinoids: reward, dependence, and underlying neurochemical mechanisms–a review of recent preclinical data publication-title: Psychopharmacol. Berl. – volume: 9 start-page: 483 year: 1969 end-page: 502 ident: bib41 article-title: Self administration of and behavioral dependence on drugs publication-title: Annu. Rev. Pharmacol. – volume: 56 start-page: 1543 year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib7 article-title: Pharmacokinetics of escalating doses of oral psilocybin in healthy adults publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-017-0540-6 – volume: 82 start-page: 31 year: 2016 ident: 10.1016/j.neuropharm.2017.11.028_bib18 article-title: An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates publication-title: J. Pharmacol. Toxicol. Methods doi: 10.1016/j.vascn.2016.07.004 – volume: 22 start-page: 603 year: 2008 ident: 10.1016/j.neuropharm.2017.11.028_bib27 article-title: Human hallucinogen research: guidelines for safety publication-title: J. Psychopharmacol. doi: 10.1177/0269881108093587 – volume: 63 start-page: 856 year: 2006 ident: 10.1016/j.neuropharm.2017.11.028_bib53 article-title: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.63.8.856 – year: 2007 ident: 10.1016/j.neuropharm.2017.11.028_bib23 – volume: 146 start-page: 92 year: 1994 ident: 10.1016/j.neuropharm.2017.11.028_bib44 article-title: Human hallucinogenic drug research: regulatory, clinical, and scientific issues publication-title: NIDA Res. Monogr. – year: 1961 ident: 10.1016/j.neuropharm.2017.11.028_bib51 – year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib10 – year: 1971 ident: 10.1016/j.neuropharm.2017.11.028_bib52 – volume: 88 start-page: 82 year: 1998 ident: 10.1016/j.neuropharm.2017.11.028_bib6 article-title: Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations publication-title: Anesthesiology doi: 10.1097/00000542-199801000-00015 – volume: 76 start-page: 247 year: 2015 ident: 10.1016/j.neuropharm.2017.11.028_bib50 article-title: Ketamine safety and tolerability in clinical trials for treatment-resistant depression publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.13m08852 – volume: 74 start-page: 250 year: 2013 ident: 10.1016/j.neuropharm.2017.11.028_bib36 article-title: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2012.06.022 – volume: 26 start-page: 224 year: 2011 ident: 10.1016/j.neuropharm.2017.11.028_bib39 article-title: A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use publication-title: Hum. Psychopharmacol. doi: 10.1002/hup.1196 – volume: 9 start-page: 483 year: 1969 ident: 10.1016/j.neuropharm.2017.11.028_bib41 article-title: Self administration of and behavioral dependence on drugs publication-title: Annu. Rev. Pharmacol. doi: 10.1146/annurev.pa.09.040169.002411 – volume: 169 start-page: 115 year: 2003 ident: 10.1016/j.neuropharm.2017.11.028_bib48 article-title: Cannabinoids: reward, dependence, and underlying neurochemical mechanisms–a review of recent preclinical data publication-title: Psychopharmacol. Berl. doi: 10.1007/s00213-003-1485-z – volume: 14 start-page: 439 year: 2006 ident: 10.1016/j.neuropharm.2017.11.028_bib29 article-title: Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults publication-title: Exp. Clin. Psychopharmacol. doi: 10.1037/1064-1297.14.4.439 – volume: 70 start-page: S55 year: 2003 ident: 10.1016/j.neuropharm.2017.11.028_bib2 article-title: Principles of drug abuse liability assessment in laboratory animals publication-title: Drug Alcohol Depend. doi: 10.1016/S0376-8716(03)00099-1 – year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib11 – volume: 30 start-page: 43 year: 1978 ident: 10.1016/j.neuropharm.2017.11.028_bib26 article-title: A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys publication-title: Bull. Narc. – volume: 23 start-page: 29 year: 1991 ident: 10.1016/j.neuropharm.2017.11.028_bib43 article-title: Human hallucinogenic drug research in the United States: a present-day case history and review of the process publication-title: J. Psychoact. Drugs doi: 10.1080/02791072.1991.10472572 – volume: 318 start-page: 421 year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib19 article-title: Marshaling FDA benefit-risk expertise to address the current opioid abuse epidemic publication-title: JAMA doi: 10.1001/jama.2017.9205 – year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib14 – volume: 70 start-page: S41 year: 2003 ident: 10.1016/j.neuropharm.2017.11.028_bib21 article-title: Principles of initial experimental drug abuse liability assessment in humans publication-title: Drug Alcohol Depend. doi: 10.1016/S0376-8716(03)00098-X – volume: 70 start-page: 5 year: 1980 ident: 10.1016/j.neuropharm.2017.11.028_bib4 article-title: Continuous-access phencyclidine self-administration by rhesus monkeys leading to physical dependence publication-title: Psychopharmacol. Berl. doi: 10.1007/BF00432363 – volume: 51 start-page: 55 year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib9 article-title: Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation publication-title: Aust. N. Z. J. Psychiatry doi: 10.1177/0004867416631828 – volume: 60 start-page: 2605 year: 2017 ident: 10.1016/j.neuropharm.2017.11.028_bib17 article-title: The 2014 Philip S. Portoghese medicinal chemistry lectureship: the “Phenylalkylaminome” with a focus on selected drugs of abuse dagger publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b00085 – volume: 68 start-page: 71 year: 2011 ident: 10.1016/j.neuropharm.2017.11.028_bib22 article-title: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer publication-title: Arch. Gen. Psychiatry doi: 10.1001/archgenpsychiatry.2010.116 – year: 2006 ident: 10.1016/j.neuropharm.2017.11.028_bib12 – volume: 83 start-page: 622 year: 2008 ident: 10.1016/j.neuropharm.2017.11.028_bib40 article-title: Assessing abuse liability during drug development: changing standards and expectations publication-title: Clin. Pharmacol. Ther. doi: 10.1038/sj.clpt.6100492 – volume: 203 start-page: 303 year: 1977 ident: 10.1016/j.neuropharm.2017.11.028_bib33 article-title: Ketamine self-administration by the rhesus monkey publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)31050-5 – year: 2006 ident: 10.1016/j.neuropharm.2017.11.028_bib37 – volume: 15 start-page: 149 year: 2004 ident: 10.1016/j.neuropharm.2017.11.028_bib13 article-title: Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys publication-title: Behav. Pharmacol. doi: 10.1097/00008877-200403000-00007 – volume: 170 start-page: 1134 year: 2013 ident: 10.1016/j.neuropharm.2017.11.028_bib34 article-title: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2013.13030392 – volume: 77 start-page: e719 year: 2016 ident: 10.1016/j.neuropharm.2017.11.028_bib25 article-title: Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.15m10056 – volume: 87 start-page: 97 year: 2014 ident: 10.1016/j.neuropharm.2017.11.028_bib8 article-title: A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.04.001 – year: 2009 ident: 10.1016/j.neuropharm.2017.11.028_bib24 – volume: 47 start-page: 351 year: 2000 ident: 10.1016/j.neuropharm.2017.11.028_bib5 article-title: Antidepressant effects of ketamine in depressed patients publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(99)00230-9 – volume: 226 start-page: 381 year: 2013 ident: 10.1016/j.neuropharm.2017.11.028_bib30 article-title: Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects publication-title: Psychopharmacol. Berl. doi: 10.1007/s00213-012-2912-9 – volume: 9 start-page: 479 year: 1998 ident: 10.1016/j.neuropharm.2017.11.028_bib15 article-title: Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers publication-title: Behav. Pharmacol. doi: 10.1097/00008877-199811000-00002 – volume: 3 start-page: 1073 year: 2000 ident: 10.1016/j.neuropharm.2017.11.028_bib49 article-title: Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys publication-title: Nat. Neurosci. doi: 10.1038/80577 – volume: 89 start-page: 683 year: 2011 ident: 10.1016/j.neuropharm.2017.11.028_bib42 article-title: Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2011.20 – volume: 18 year: 2015 ident: 10.1016/j.neuropharm.2017.11.028_bib31 article-title: Salvinorin-a induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyv065 – year: 2014 ident: 10.1016/j.neuropharm.2017.11.028_bib20 – volume: 73 start-page: 121 year: 1996 ident: 10.1016/j.neuropharm.2017.11.028_bib45 article-title: Human psychopharmacology of N,N-dimethyltryptamine publication-title: Behav. Brain Res. doi: 10.1016/0166-4328(96)00081-2 – volume: 70 start-page: S13 year: 2003 ident: 10.1016/j.neuropharm.2017.11.028_bib3 article-title: Guidelines and methodological reviews concerning drug abuse liability assessment publication-title: Drug Alcohol Depend. doi: 10.1016/S0376-8716(03)00097-8 – volume: 72 start-page: 414 year: 2011 ident: 10.1016/j.neuropharm.2017.11.028_bib35 article-title: A case of sustained remission following an acute course of ketamine in treatment-resistant depression publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.10l06447blu – volume: 67 start-page: 139 year: 2010 ident: 10.1016/j.neuropharm.2017.11.028_bib1 article-title: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2009.08.038 – volume: 51 start-page: 85 year: 1994 ident: 10.1016/j.neuropharm.2017.11.028_bib46 article-title: Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1994.03950020009001 – volume: 51 start-page: 98 year: 1994 ident: 10.1016/j.neuropharm.2017.11.028_bib47 article-title: Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1994.03950020022002 – volume: 66 start-page: 522 year: 2009 ident: 10.1016/j.neuropharm.2017.11.028_bib38 article-title: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2009.04.029 – volume: 27 start-page: 385 year: 1987 ident: 10.1016/j.neuropharm.2017.11.028_bib32 article-title: Animal models of intravenous phencyclinoid self-administration publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/0091-3057(87)90587-9 – volume: 169 start-page: 135 year: 2003 ident: 10.1016/j.neuropharm.2017.11.028_bib28 article-title: Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys publication-title: Psychopharmacol. Berl. doi: 10.1007/s00213-003-1484-0 – volume: 24 start-page: 229 year: 2016 ident: 10.1016/j.neuropharm.2017.11.028_bib16 article-title: Clinical applications of hallucinogens: a review publication-title: Exp. Clin. Psychopharmacol. doi: 10.1037/pha0000084 |
| SSID | ssj0004818 |
| Score | 2.3395102 |
| SecondaryResourceType | review_article |
| Snippet | In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 135 |
| SubjectTerms | Abuse potential hallucinogens Animals Controlled hallucinogens Drug and Narcotic Control - methods Hallucinogens - adverse effects Hallucinogens - therapeutic use Hallucinogens regulations Humans Substance-Related Disorders - prevention & control |
| Title | A regulatory perspective on the evaluation of hallucinogen drugs for human use |
| URI | https://dx.doi.org/10.1016/j.neuropharm.2017.11.028 https://www.ncbi.nlm.nih.gov/pubmed/29180224 https://www.proquest.com/docview/1969934638 |
| Volume | 142 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF6KXryIb-ujrCA9GW2SzW6CpyKWqlh6qOBtyW52pSJJaZtDL_52Z_JoEBQEjwkZstmZnZndfPMNIZc24JpbETg9oSKH-XHgKG09RBGCBSQebJ2xUPh5xIcv7PE1eG2Ru7oWBmGVle8vfXrhras7N9Vs3symU6zxhdAYQUgDIw18gYyfjAm08uvPBubBQjesmZjx6QrNU2K8Cs7IGXJEI8hLXCOfJ_Zl_zlE_ZaCFqFosEO2qxyS9sth7pKWSfdId1ySUK-u6KSpqVpc0S4dN_TUq30y6tN52YA-m6_orCm2pFlKIR2kDQE4zSzFZiu5nqYZWBpN5vnbgkKeS4vefjRfmAPyMrif3A2dqquCo2G9Lh1IeCLrJUawBOnqlFZ4_iEiboNAJTp2lStMz_gm8WNfaI9pHisRMqZc3QMx_5BspFlqjgmF5WvwSITFgWKWWyV6XHHBtWbMt0y3iagnUuqKchw7X3zIGlv2LhsVSFQB7EgkqKBN3LXkrKTd-IPMba0r-c2EJESHP0hf1OqVsMLwt0mcmixfSCQQgm8ER9UmR6Xe12PyImTQ89jJv959SrbgKixLHM_IxnKem3PIdZaqUxhzh2z2H56Goy8G2gCN |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VcoAL4s3yHCToqWk3iWNvhDhUQLWl7aqHrdSbiR0bLULJarMR2gt_ij_ITB6NkECqhHpN5MSZGc-MnZnvA3jjE2mlV0kwViYNRJwlgbE-4ipCsoA8oq0zNwqfzuT0XHy-SC624FffC8NllZ3vb3164627K_udNPeXiwX3-FJoTCmkkZEmseoZrI_d5gft26r3Rx9JyW-j6PDT_MM06KgFAktGuw4o6qc-yp0SOWO2GWv4EECl0ieJyW0WmlC5sYtdHmexspGwMjNqIoQJ7ZiGxfTcG3BTkLtg2oS9n0NdiZiEkx76mafXlQ-1RWUNSOWSQam5qkztMYAoE8H_PSb-K-dtYt_hXbjTJa140MrlHmy54j7snLWo15tdnA9NXNUu7uDZgIe9eQCzA1y1jPflaoPLobsTywIp_8QBcRxLj8zuUttFUZJpY76qv1ZIiTU2ZIJYV-4hnF-LrB_BdlEW7gkg-QvHZzAiS4zw0hs1lkYqaa0QsRd2BKoXpLYdxjlTbXzXfTHbNz2oQLMKaAukSQUjCC9HLlucjyuMedfrSv9hs5rC0RVGv-7Vq2lJ83-arHBlXWlGLKJvJM84gset3i_nFKUM2ReJp__17ldwazo_PdEnR7PjZ3Cb7kza_srnsL1e1e4FJVpr87IxbIQv172SfgPBYzyF |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+regulatory+perspective+on+the+evaluation+of+hallucinogen+drugs+for+human+use&rft.jtitle=Neuropharmacology&rft.au=Calderon%2C+Silvia+N.&rft.au=Hunt%2C+Joshua&rft.au=Klein%2C+Michael&rft.date=2018-11-01&rft.pub=Elsevier+Ltd&rft.issn=0028-3908&rft.eissn=1873-7064&rft.volume=142&rft.spage=135&rft.epage=142&rft_id=info:doi/10.1016%2Fj.neuropharm.2017.11.028&rft.externalDocID=S0028390817305373 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3908&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3908&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3908&client=summon |